These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36871952)

  • 1. Flow cell sorting followed by PCR-based clonality testing may assist in questionable diagnosis and monitoring of acute lymphoblastic leukemia.
    Semchenkova A; Zhogov V; Zakharova E; Mikhailova E; Illarionova O; Larin S; Novichkova G; Karachunskiy A; Maschan M; Popov A
    Int J Lab Hematol; 2023 Aug; 45(4):506-515. PubMed ID: 36871952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
    Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
    Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
    Chatterjee G; Dhende P; Raj S; Shetty V; Ghogale S; Deshpande N; Girase K; Patil J; Kalra A; Narula G; Dalvi K; Dhamne C; Moulik NR; Rajpal S; Patkar NV; Banavali S; Gujral S; Subramanian PG; Tembhare PR
    Eur J Haematol; 2024 Jan; 112(1):122-136. PubMed ID: 37706583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease.
    Momen N; Tario J; Fu K; Qian YW
    J Hematop; 2023 Jun; 16(2):85-94. PubMed ID: 38175444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
    Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
    Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
    Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
    Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
    Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
    Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements.
    Popov A; Tsaur G; Verzhbitskaya T; Riger T; Permikin Z; Demina A; Mikhailova E; Shorikov E; Arakaev O; Streneva O; Khlebnikova O; Makarova O; Miakova N; Fominikh V; Boichenko E; Kondratchik K; Ponomareva N; Novichkova G; Karachunskiy A; Fechina L
    Br J Haematol; 2023 May; 201(3):510-519. PubMed ID: 34970734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
    Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
    Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.
    Verbeek MWC; van der Velden VHJ
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor B-cell lymphoblastic leukemia.
    Jo I; Chung NG; Lee S; Kwon A; Kim J; Choi H; Jang W; Kim S; Lee JW; Yoon JH; Cho B; Han K; Kim Y; Kim M
    Clin Chim Acta; 2019 Jan; 488():81-89. PubMed ID: 30389459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimerism evaluation in measurable residual disease-suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
    Semchenkova A; Brilliantova V; Shelikhova L; Zhogov V; Illarionova O; Mikhailova E; Raykina E; Skorobogatova E; Novichkova G; Maschan A; Maschan M; Popov A
    Cytometry B Clin Cytom; 2021 Sep; 100(5):568-573. PubMed ID: 33369016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
    Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods.
    Øbro NF; Ryder LP; Madsen HO; Andersen MK; Lausen B; Hasle H; Schmiegelow K; Marquart HV
    Haematologica; 2012 Jan; 97(1):137-41. PubMed ID: 21933850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia.
    Ramos Elbal E; Fuster JL; Campillo JA; Galera AM; Cortés MB; Llinares ME; Jiménez I; Plaza M; Martínez Banaclocha H; Galián JA; Blanquer Blanquer M; Martínez Sánchez MV; Muro M; Minguela A
    Clin Transl Oncol; 2024 Jan; 26(1):278-287. PubMed ID: 37368200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How I investigate minimal residual disease in acute lymphoblastic leukemia.
    Correia RP; Bento LC; de Sousa FA; Barroso RS; Campregher PV; Bacal NS
    Int J Lab Hematol; 2021 Jun; 43(3):354-363. PubMed ID: 33423385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.
    Popov A; Henze G; Tsaur G; Budanov O; Roumiantseva J; Belevtsev M; Verzhbitskaya T; Movchan L; Lagoyko S; Zharikova L; Olshanskaya Y; Riger T; Valochnik A; Miakova N; Litvinov D; Khlebnikova O; Streneva O; Stolyarova E; Ponomareva N; Novichkova G; Aleinikova O; Fechina L; Karachunskiy A
    Cancer Med; 2024 Apr; 13(8):e7172. PubMed ID: 38651186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment.
    Chatterjee G; Dudakia V; Ghogale S; Deshpande N; Girase K; Chaturvedi A; Shetty D; Senger M; Jain H; Bagal B; Bonda A; Punatar S; Gokarn A; Khattry N; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Int J Lab Hematol; 2021 Oct; 43(5):990-999. PubMed ID: 33432783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between a 10-color flow cytometric measurable residual disease (MRD) analysis and molecular MRD in adult B-acute lymphoblastic leukemia.
    Singh J; Gorniak M; Grigoriadis G; Westerman D; McBean M; Venn N; Law T; Sutton R; Morgan S; Fleming S
    Cytometry B Clin Cytom; 2022 Mar; 102(2):115-122. PubMed ID: 34806309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.